|
The following stocks are the leading risers and fallers on AIM on Monday. ---------- AIM - WINNERS ---------- MobilityOne Ltd, up 86% at 6.50 pence, 12-month range 6.90p-0.70p. Shares in the Kuala Lumpur-based e-commerce payment solutions provider continue to rise after they more than doubled last Wednesday. Last week, the firm said its Malaysia subsidiary receives conditional approval from Labuan’s financial services authority to establish an additional subsidiary to carry on its Islamic digital banking business. The firm says its wholly-owned subsidiary MobilityOne Sdn Bhd, also known as M1 Malaysia, will establish a subsidiary in Labuan to be named MBO Bank (Labuan). MobilityOne says the purpose of MBO Bank is to offer a ‘full suite of offshore financial services’ through a Shariah-compliant platform to international clients, under the Labuan Financial Services Authority regulatory framework. Due to the preparatory work required to meet the conditions of Labuan FSA approval, MobilityOne says it does not anticipate to record any revenue or earnings from the Islamic digital banking business in 2026. ---------- Touchstone Exploration Inc, up 23% at 9.00p, 12-month range 29.00p-5.70p. The onshore oil and gas producer in Trinidad says the Carapal Ridge-3 development well, in which it holds a 65% operating working interest, encountered 1,082 feet of net sand, including around 1,000 feet of net Herrera sand. It is the first well drilled into the Carapal Ridge pool in the past 17 years. It says completion operations are underway, with tie-in to the Central block natural gas processing facility targeted for the first quarter of 2026. The well supports the potential for up to three more Herrera development wells on the Central block. ‘The well was executed successfully by our drilling team and represents our first horizontal well drilled into the Herrera reservoir,’ says Chief Executive Officer Paul Baay. ‘As anticipated, CR-3 encountered hydrocarbon-bearing sands both below and above a key shale marker. We intend to initially produce from the lower horizontal section of the well, with significant volumes of uphole sands available for potential future perforation. While the well has resulted in thick pay zone across multiple horizons, the ultimate deliverability will not be known until the well is completed and tied into the facility.’ ---------- AIM - LOSERS ---------- accesso Technology Group PLC, down 16% at 272.19p, 12-month range 552.00p-270.00p. The Berkshire, England-based provider of software for the leisure, entertainment and cultural sector says a major customer has indicated its intention not to renew its agreement for a software solution beyond its contractual expiry on January 31. Another customer that was not expected to continue beyond the end of 2025 now plans to renew its contract for one year, accesso adds. The firm expects to report a full year outturn in line with expectations. ‘While the combined financial impact of the recent contract developments is still dependent upon the outcome of negotiations, the board currently expects the net revenue impact to be offset, at a cash [earnings before interest, tax, depreciation and amortisation] level, by current initiatives focused on further improving our operational efficiency,’ accesso says. ---------- TheraCryf PLC, down 9.0% at 0.18p, 12-month range 1.25p-0.18p. The Cheshire, England-based pharmaceutical firm focused on cancer treatment and brain disorders establishes the process for large-scale manufacturing of Ox-1 orexin blocker, a potential treatment for addictive disorders. It achieves scale-up on schedule with a manufacturing yield in excess of the target. The firm produces 10.6 kilograms to supply 28-day regulatory toxicology studies. TheraCryf adds that dosing in two species has now started to identify the maximum tolerated dose for the studies. The studies will begin in the first half of 2026 and are scheduled to complete in the third quarter. ‘We are pleased to have achieved this key milestone in the development of our potentially class leading orexin blocker programme, on schedule. These activities are critical to generating a robust data package to enable human trials and we are on track to deliver them during 2026,’ says Chief Operating Officer Helen Kuhlman. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
